GDC-0834 - CAS 1133432-46-8
Catalog number:
1133432-46-8
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
COA:
Inquire
Targets:
BTK
Description:
GDC-0834 is a potent and selective inhibitor of Bruton's tyrosine kinase (BTK), investigated as a potential treatment for rheumatoid arthritis. In vitro metabolite identification studies in hepatocytes revealed predominant formation of an inactive metabolite (M1) via amide hydrolysis in human.
Publictions citing BOC Sciences Products
  • >> More
Synonyms:
GDC-0834; GDC0834; GDC 0834
MSDS:
Inquire
Current Developer:
Genentech.
1.Potent and selective Bruton's tyrosine kinase inhibitors: discovery of GDC-0834.
Young WB1, Barbosa J2, Blomgren P2, Bremer MC1, Crawford JJ1, Dambach D1, Gallion S3, Hymowitz SG1, Kropf JE2, Lee SH2, Liu L1, Lubach JW1, Macaluso J2, Maciejewski P2, Maurer B1, Mitchell SA2, Ortwine DF1, Di Paolo J2, Reif K1, Scheerens H1, Schmitt A2, Bioorg Med Chem Lett. 2015 Mar 15;25(6):1333-7. doi: 10.1016/j.bmcl.2015.01.032. Epub 2015 Feb 7.
SAR studies focused on improving the pharmacokinetic (PK) properties of the previously reported potent and selective Btk inhibitor CGI-1746 (1) resulted in the clinical candidate GDC-0834 (2), which retained the potency and selectivity of CGI-1746, but with much improved PK in preclinical animal models. Structure based design efforts drove this work as modifications to 1 were investigated at both the solvent exposed region as well as 'H3 binding pocket'. However, in vitro metabolic evaluation of 2 revealed a non CYP-mediated metabolic process that was more prevalent in human than preclinical species (mouse, rat, dog, cyno), leading to a high-level of uncertainly in predicting human pharmacokinetics. Due to its promising potency, selectivity, and preclinical efficacy, a single dose IND was filed and 2 was taken in to a single dose phase I trial in healthy volunteers to quickly evaluate the human pharmacokinetics. In human, 2 was found to be highly labile at the exo-cyclic amide bond that links the tetrahydrobenzothiophene moiety to the central aniline ring, resulting in insufficient parent drug exposure.
2.A novel reaction mediated by human aldehyde oxidase: amide hydrolysis of GDC-0834.
Sodhi JK1, Wong S2, Kirkpatrick DS2, Liu L2, Khojasteh SC2, Hop CE2, Barr JT2, Jones JP2, Halladay JS2. Drug Metab Dispos. 2015 Jun;43(6):908-15. doi: 10.1124/dmd.114.061804. Epub 2015 Apr 6.
GDC-0834, a Bruton's tyrosine kinase inhibitor investigated as a potential treatment of rheumatoid arthritis, was previously reported to be extensively metabolized by amide hydrolysis such that no measurable levels of this compound were detected in human circulation after oral administration. In vitro studies in human liver cytosol determined that GDC-0834 (R)-N-(3-(6-(4-(1,4-dimethyl-3-oxopiperazin-2-yl)phenylamino)-4-methyl-5-oxo- 4,5-dihydropyrazin-2-yl)-2-methylphenyl)-4,5,6,7-tetrahydrobenzo[b] thiophene-2-carboxamide) was rapidly hydrolyzed with a CLint of 0.511 ml/min per milligram of protein. Aldehyde oxidase (AO) and carboxylesterase (CES) were putatively identified as the enzymes responsible after cytosolic fractionation and mass spectrometry-proteomics analysis of the enzymatically active fractions. Results were confirmed by a series of kinetic experiments with inhibitors of AO, CES, and xanthine oxidase (XO), which implicated AO and CES, but not XO, as mediating GDC-0834 amide hydrolysis.
3.Validation and application of a liquid chromatography-tandem mass spectrometric method for the determination of GDC-0834 and its metabolite in human plasma using semi-automated 96-well protein precipitation.
Shin YG1, Jones SA, Murakami SC, Liu L, Wong H, Buonarati MH, Hop CE. Biomed Chromatogr. 2012 Nov;26(11):1444-51. doi: 10.1002/bmc.2716. Epub 2012 Feb 7.
A liquid chromatographic-tandem mass spectrometric (LC-MS/MS) method was developed and validated for the determination of GDC-0834 and its amide hydrolysis metabolite (M1) in human plasma to support clinical development. The method consisted of semi-automated 96-well protein precipitation extraction for sample preparation and LC-MS/MS analysis in positive ion mode using TurboIonSpray® for analysis. D6-GDC-0834 and D6-M1 metabolite were used as internal standards. A linear regression (weighted 1/concentration(2) ) was used to fit calibration curves over the concentration range of 1 - 500 ng/mL for both GDC-0834 and M1 metabolite. The accuracy (percentage bias) at the lower limit of quantitation (LLOQ) was 5.20 and 0.100% for GDC-0834 and M1 metabolite, respectively. The precision (CV) for samples at the LLOQ was 3.13-8.84 and 5.20-8.93% for GDC-0834 and M1 metabolite, respectively. For quality control samples at 3, 200 and 400 ng/mL, the between-run CV was ≤ 7.
4.Significant species difference in amide hydrolysis of GDC-0834, a novel potent and selective Bruton's tyrosine kinase inhibitor.
Liu L1, Halladay JS, Shin Y, Wong S, Coraggio M, La H, Baumgardner M, Le H, Gopaul S, Boggs J, Kuebler P, Davis JC Jr, Liao XC, Lubach JW, Deese A, Sowell CG, Currie KS, Young WB, Khojasteh SC, Hop CE, Wong H. Drug Metab Dispos. 2011 Oct;39(10):1840-9. doi: 10.1124/dmd.111.040840. Epub 2011 Jul 8.
(R)-N-(3-(6-(4-(1,4-dimethyl-3-oxopiperazin-2-yl)phenylamino)-4-methyl-5-oxo-4,5-dihydropyrazin-2-yl)-2-methylphenyl)-4,5,6,7-tetrahydrobenzo[b]thiophene-2-carboxamide (GDC-0834) is a potent and selective inhibitor of Bruton's tyrosine kinase (BTK), investigated as a potential treatment for rheumatoid arthritis. In vitro metabolite identification studies in hepatocytes revealed predominant formation of an inactive metabolite (M1) via amide hydrolysis in human. The formation of M1 appeared to be NADPH-independent in human liver microsomes. M1 was found in only minor to moderate quantities in plasma from preclinical species dosed with GDC-0834. Human clearance predictions using various methodologies resulted in estimates ranging from low to high. In addition, GDC-0834 exhibited low clearance in PXB chimeric mice with humanized liver. Uncertainty in human pharmacokinetic prediction and high interest in a BTK inhibitor for clinical evaluation prompted an investigational new drug strategy, in which GDC-0834 was rapidly advanced to a single-dose human clinical trial.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related BTK Products


CAS 1353550-13-6 Olmutinib

Olmutinib
(CAS: 1353550-13-6)

Olmutinib, also called as HM61713 and BI-1482694, is an orally available, mutant-selective third-generation epidermal growth factor receptor tyrosine kinase inh...

CAS 1133432-49-1 GDC-0837

GDC-0837
(CAS: 1133432-49-1)

GDC-0834 is a small molecule inhibitor of Btk potentially useful in the treatment of RA and lymphoid malignancies. Administration of GDC-0834 (30 -- 100 mg/kg)...

CAS 1360053-81-1 AVL-292 benzenesulfonate

AVL-292 benzenesulfonate
(CAS: 1360053-81-1)

AVL-292 benzenesulfonate is a covalent, highly selective, orally active small molecule inhibitor of Btk with IC50 value of 0.5 nM; >1400-fold selectivity ove...

CAS 1022150-12-4 Btk inhibitor 1 R enantiomer

Btk inhibitor 1 R enantiomer
(CAS: 1022150-12-4)

Btk inhibitor 1 R enantiomer is a pyrazolo[3,4-d]pyrimidine derivative as a Btk kinase inhibitor.

CAS 1553977-42-6 Btk inhibitor 1 R enantiomer hydrochloride

Btk inhibitor 1 R enantiomer hydrochlori
(CAS: 1553977-42-6)

Btk inhibitor 1R enantiomer Hcl is a&nbsp; pyrazolo[3,4-d]pyrimidine derivative as a <strong>Btk </strong>kinase inhibitor.

CAS 936563-87-0 PCI-32765 Racemate

PCI-32765 Racemate
(CAS: 936563-87-0)

PCI-32765 Racemate is a potent and highly selective inhibitor of Bruton tyrosine kinase (BTK), modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, ...

CAS 1133432-46-8 GDC-0834

GDC-0834
(CAS: 1133432-46-8)

GDC-0834 is a potent and selective inhibitor of Bruton's tyrosine kinase (BTK), investigated as a potential treatment for rheumatoid arthritis. In vitro metabol...

CAS 910232-84-7 CGI1746

CGI1746
(CAS: 910232-84-7)

CGI1746 is a small-molecule Btk inhibitor chemotype with a new binding mode that stabilizes an inactive nonphosphorylated enzyme conformation. CGI1746 has exqui...

ONO-4059 (hydrochloride)
(CAS: 1439901-97-9)

ONO-4059 (hydrochloride) is the hydrochloride salt form of Tirabrutinib. ONO-4059 is a highly selective, orally bioavailable BTK inhibitor (IC50= 2.2 nM) and de...

CAS 1202757-89-8 AVL-292

AVL-292
(CAS: 1202757-89-8)

AVL-292, also known as CC-292, is an orally bioavailable, selective inhibitor of Bruton’s agammaglobulinemia tyrosine kinase (BTK), with potential antineoplas...

CAS 936563-96-1 PCI-32765 (Ibrutinib)

PCI-32765 (Ibrutinib)
(CAS: 936563-96-1)

Ibrutinib is a small-molecule inhibitor of Bruton's tyrosine kinase (BTK). It binds to BTK to suppress both B-cell activation and B-cell-mediated signaling.

CAS 330786-25-9 PCI 29732

PCI 29732
(CAS: 330786-25-9)

Potent BTK inhibitor (IC50 = 0.3 nM). Blocks B cell antigen receptor (BCR)-mediated gene expression in CD20+ B cells.

CAS 1242156-23-5 RN486

RN486
(CAS: 1242156-23-5)

RN486 is a reversible Bruton's tyrosine kinase (Btk) inhibitor with IC50 value of 4.0 nM.

ONO-4059 analogue
(CAS: 1351635-67-0)

ONO-4059 analogue is an analogue of ONO-4059, which is a highly potent and selective oral BTK inhibitor with IC50 of 23.9 nM. Phase 1.

CAS 1202759-32-7 CNX-774

CNX-774
(CAS: 1202759-32-7)

CNX-774 is a potent Btk inhibitor (IC50 < 1 nM)

CAS 1415823-73-2 Evobrutinib

Evobrutinib
(CAS: 1415823-73-2)

Evobrutinib is a highly selective inhibitor of Bruton's tyrosin kinase (Btk) inhibitor.

RN983
(CAS: 1423129-83-2)

RN983 is a selective BTK enzyme inhibitor. It inhibits IgG production in B-cells with an IC50 value of 2.5 ± 0.7 nM and PGD2 production from mast cells with an ...

CAS 1633350-06-7 BGB-3111

BGB-3111
(CAS: 1633350-06-7)

BGB-3111 is a potent, selective and orally available Bruton's tyrosine kinase (Btk) inhibitor that demonstrates superior oral bioavailability, achieving higher ...

CAS 1412418-47-3 Btk inhibitor 1

Btk inhibitor 1
(CAS: 1412418-47-3)

Btk inhibitor 1 is a pyrazolo[3,4-d]pyrimidine derivative as a Btk kinase inhibitor.

ONO-4059
(CAS: 1351636-18-4)

ONO-4059, a BTK inhibitor, has been found to have potential effect against sorts of malignancies by influencing the B-cell development. It is currently under Ph...

Chemical Structure

CAS 1133432-46-8 GDC-0834

Quick Inquiry

Verification code

Featured Items